Health Blueprint

Back to Longevity News

News summary

CellCarta and Imagene AI Expand Collaboration to Validate, Deploy and Scale AI-Powered Biomarker and Companion Diagnostic Programs Across Drug Development

Source: PR Newswire • Published: 01 Oct 2026, 13:15

Summarized by Masters of Longevity from PR Newswire.

AI-powered biomarker and companion diagnostic development: a news article outlining an expanded industry partnership that offers a coordinated path to validate, deploy, and scale these programs across drug development.

CellCarta and Imagene AI Expand Collaboration to Validate, Deploy and Scale AI-Powered Biomarker and Companion Diagnostic Programs Across Drug Development
Key Takeaways
  • 1, 2026 /PRNewswire/ -- CellCarta and Imagene AI today announced an expanded collaboration to provide a coordinated path for biopharma companies to validate, deploy, and scale AI-powered biomarker and companion diagnostic (CDx) programs.
  • The collaboration is designed to support programs from biomarker strategy and assay development through validation, clinical trial execution, regulatory readiness, and deployment.
  • The companies are currently working together on programs with two leading global pharmaceutical companies.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.